- Data from the FLOW Renal Outcomes trial evaluating the efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes1
- Data from the SELECT Cardiovascular Outcomes trial evaluating the efficacy and safety of semaglutide 2.4 mg once weekly in people with obesity and a history of cardiovascular disease but without diabetes2
- Data from the STEP HFpEF trial programme evaluating the efficacy and safety of once-weekly semaglutide 2.4 mg in patients with obesity-related heart failure (HFpEF) with and without diabetes3,Four
Bagsvaer, Denmark, June 18, 2024 Novo Nordisk today released 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th International Pharmacology Conference.Number American Diabetes Association (ADA) Scientific Meeting. The meeting will be held in Orlando, USA from June 21-24, 2024 in-person and virtual formats.
Additional data from three landmark trials with semaglutide will also be presented in dedicated scientific sessions, which will evaluate additional potential benefits of semaglutide, including assessing renal and cardiovascular endpoints in patients with type 2 diabetes and chronic kidney disease (FLOW, semaglutide 1.0 mg), and cardiovascular and glycemic-related endpoints in patients with obesity and CVD with or without diabetes (SELECT and STEP HFpEF, semaglutide 2.4 mg).
“We know that cardiovascular disease, chronic kidney disease, obesity and cardiometabolic diseases such as type 2 diabetes are often inter-related and can occur in the same patients. We need to develop medicines that address different aspects of these diseases,” said Stephen Goff, senior vice president and global chief medical officer at Novo Nordisk. “The extensive data being presented at ADA this year reflects this goal. In particular, the FLOW and SELECT data look at how we treat common comorbidities of diabetes and obesity, such as kidney disease and cardiovascular disease.”
All abstracts will be published on the journal’s website. Diabetes®Data from the scientific sessions will be made publicly available following presentation.
Presentation Summary
Scientific Sessions
The following data will be presented in dedicated scientific sessions as part of the scientific agenda of the meeting:
| First Renal Outcomes Trial with Once-Weekly GLP1-RA Semaglutide – Results from the FLOW Study (Scientific Session; June 24, 13:30-15:00 EST) |
| SELECT Trial – New Insights into Blood Glucose, Inflammation, and Heart Failure (Scientific Sessions, June 22, 8:00-9:00 ET) |
| STEP-HFpEF and STEP-HFpEF-DM Trials – Targeting Obesity for Heart Failure Treatment (Scientific Sessions; June 23, 16:30-18:00 EST) |
Poster and oral presentations
The following abstract was submitted by Novo Nordisk and accepted for presentation at the conference.
| Diabetes |
| Ozempic® (Semaglutide 1.0 mg once weekly) |
|
|
|
|
|
| Rubelsus® (Once-daily oral semaglutide) |
|
|
| Kagrisema |
|
| Once-weekly insulin Icodek |
|
|
|
|
|
|
|
|
|
|
|
| Daily insulin |
|
|
| Common diabetes |
|
|
|
|
|
|
| Digital Health |
|
|
| obesity |
| Wegovi® (Semaglutide 2.4mg once weekly) |
|
|
|
| General obesity |
|
|
About Ozempic®
Semaglutide, administered subcutaneously once weekly, is approved in doses of 0.5 mg, 1.0 mg and 2.0 mg under the brand name Ozempic.® It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes and a history of cardiovascular disease.
About Rybelsus®
Oral semaglutide is taken once daily and is approved for use in three therapeutic doses: 3 mg, 7 mg and 14 mg under the brand name Rybelsus.®It is indicated for the treatment of adults with poorly controlled type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise.
About Wegovy®
Semaglutide 2.4 mg administered subcutaneously once weekly is approved under the brand name Wegovy.® It is also indicated, in combination with a calorie-restricted diet and increased physical activity, to reduce the risk of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in obese or overweight adults with a history of cardiovascular disease, and to reduce excess weight and maintain weight loss over the long term in obese adults and pediatric patients aged 12 years and older, and in overweight adults with at least one weight-related comorbidity.
About Novo Nordisk
Founded in 1923, Novo Nordisk is a leading global healthcare company headquartered in Denmark. Building on our heritage in diabetes, our purpose is to drive transformation to overcome serious chronic diseases. We are pioneering scientific breakthroughs, expanding access to medicines and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 66,000 people in 80 countries and markets products in approximately 170 countries. For more information, please visit www.novonordisk.com/. Novo Nordisk, Facebook, Instagram, X, LinkedIn and Youtube.
For more information contact:
_______________________
References
1. ClinicalTrials.gov. Study of How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW). Available at: https://clinicaltrials.gov/study/NCT03819153. Last accessed June 2024.
2. ClinicalTrials.gov. Effect of Semaglutide on Heart Disease and Stroke in Overweight or Obese Patients (SELECT). Available at: https://clinicaltrials.gov/study/NCT03574597. Last accessed June 2024.
3. ClinicalTrials.gov. Study of Semaglutide in Patients with Heart Failure and Obesity (STEP-HFpEF). Available at: https://clinicaltrials.gov/study/NCT04788511. Last accessed June 2024.
4. ClinicalTrials.gov. Study of Semaglutide in Patients with Heart Failure, Obesity, and Type 2 Diabetes (STEP HFpEF DM). Available at: https://clinicaltrials.gov/study/NCT04916470. Last accessed June 2024.
-
PR240618-ADA_Global Curtain Riser
